In this regard, TSA treatment can enhance the expression of NKG2D ligands [35] on tumor cells, which may activate NK cell mediated immune responses and synergize with CD28 in inducing proliferation and IFN-γ production by CD8+ T cells [36]. The gene discussed is IFNG; the disease is neoplasm.